Kymera Therapeutics, Inc. (KYMR) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to its investigational drug KT-621 for the treatment of moderate to severe eosinophilic asthma.
KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial in eosinophilic asthma, with data expected in late 2027. The company is also conducting the BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis, with results anticipated by mid-2027.
Kymera noted that KT-621 had previously received Fast Track designation in atopic dermatitis.
Shares of Kymera Therapeutics closed at $85.05 on Friday, down 2.63%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.